Share
One of the early ÃÛÌÒ´«Ã½-supported consortia studying C9orf72 ALS put forward the idea that it may be possible to treat ALS by targeting C9orf72 peptides directly. To move this idea forward, ÃÛÌÒ´«Ã½ connected , a biotechnology company with a group of scientists with niche expertise in cellular and animal models of ALS. ÃÛÌÒ´«Ã½ then funded this new collaboration to accelerate the development of antibodies against C9orf72, which were tested in mouse models of the disease.
At the 2018 Annual Meeting of ÃÛÌÒ´«Ã½, Neurimmune announced the development of a potential therapeutic option and discussed plans to launch a Phase I clinical trial on an accelerated schedule.
